Pharma companies are less concerned after hearing from the US about negotiated Medicare prices
By Patrick Wingrove and Michael Erman (Reuters) – Four pharmaceutical companies involved in the first U.S. negotiations on Medicare program prices say they do not expect a major impact on their businesses after seeing secret price recommendations from to the government for their drugs that will be effective in 2026. The chief executives of Bristol … Read more